(Q39026942)

8 September 2017

Therapeutic management of severe relapses in multiple sclerosis (English)

1 reference

8 September 2017

0 references

Carolyn Bevan

1

1 reference

PubMed ID

25794777

8 September 2017

Jeffrey M Gelfand

series ordinal

2

1 reference

8 September 2017

1 April 2015

1 reference

Current treatment options in neurology

8 September 2017

1 reference

8 September 2017

17

1 reference

8 September 2017

4

1 reference

8 September 2017

345

1 reference

https://scigraph.springernature.com/pub.10.1007/s11940-015-0345-6

8 September 2017

0 references

cites work

Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Acute demyelinating lesions with restricted diffusion in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

MRI outcomes in the diagnosis and disease course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Understanding pseudo: the symptoms are real, the cause is unclear

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Relapse management in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Treatment of acute relapses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Beneficial plasma exchange response in central nervous system inflammatory demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Immunosuppressive treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

'Time is brain' also in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

New management algorithms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Immunosuppressive treatments in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Intravenous immunoglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis--the Israeli experience. MS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

How to treat tumefactive demyelinating disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Neurological picture. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Rituximab for tumefactive inflammatory demyelination: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Tumefactive demyelination: an approach to diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Cyclophosphamide therapy in pediatric multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Outcome measurement in multiple sclerosis: detection of clinically relevant improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Management of pain in multiple sclerosis: a pharmacological approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Prevalence and treatment of spasticity reported by multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Symptomatic therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Functional treatments in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Multiple sclerosis: Prospects and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-015-0345-6

Multiple sclerosis: A serial study using MRI in relapsing patients

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Corticosteroids or ACTH for acute exacerbations in multiple sclerosis

1 reference

12 December 2020

Disease-modifying agents in multiple sclerosis

1 reference

12 December 2020

A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis

1 reference

12 December 2020

High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Plasma exchange for severe attacks of CNS demyelination: predictors of response

1 reference

12 December 2020

Diffusion magnetic resonance imaging in multiple sclerosis.

1 reference

12 December 2020

Persistent pain and uncomfortable sensations in persons with multiple sclerosis

1 reference

12 December 2020

Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS

1 reference

12 December 2020

Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis

1 reference

12 December 2020

The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.)

1 reference

12 December 2020

Influence of infection on exacerbations of multiple sclerosis

1 reference

12 December 2020

Improving quality of life in multiple sclerosis: an unmet need.

1 reference

12 December 2020

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

12 December 2020

Effects of ACTH and cortisone in multiple sclerosis.

1 reference

12 December 2020

A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis

1 reference

12 December 2020

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

1 reference

12 December 2020

Multiple sclerosis relapses: a multivariable analysis of residual disability determinants

1 reference

12 December 2020

Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.

1 reference

12 December 2020

10.1007/S11940-015-0345-6

Identifiers

DOI

1 reference

8 September 2017

1 reference

PubMed ID

25794777